Nad+ Sublingual Drops

Nanoparticle transdermal absorption technology encapsulates nicotinamide adenine dinucleotide molecules within carriers such as liposomes or solid lipid nanoparticles, forming particles with diameters of 100–200 nanometers. Leveraging the small size and high specific surface area of these nanoparticles, it overcomes the barrier of the stratum corneum. For instance, multilamellar liposome technology encapsulates NAD+ within phospholipid bilayers. Phosphate components on the liposome surface specifically bind to receptors on cell membranes, inducing membrane invagination to form vesicles that deliver nicotinamide adenine dinucleotide directly into the cytoplasm. Experimental data show this technology increases cellular nicotinamide adenine dinucleotide absorption rates to 89%, over six times higher than traditional oral administration.

The core advantage of transdermal technology lies in its targeting capability. By modifying the liposome surface with specific ligands (such as the anti-aging cell surface marker CD9), nicotinamide adenine dinucleotide can be precisely delivered to high-energy-consuming tissues like brain neurons and cardiomyocytes. For example, DEON Laboratories' HLNAD+ product employs a dual-targeted design: its neuroprotective layer activates the Sirt1/3 pathway to elevate brain-derived neurotrophic factor (BDNF) levels, while its metabolic regulation layer suppresses the NF-κB inflammatory pathway to reduce oxidative stress damage. A double-blind clinical trial demonstrated that after 8 weeks of continuous use, participants experienced a 35% increase in brain nicotinamide adenine dinucleotide concentration and a 28% reduction in the inflammatory marker IL-6.

Transdermal delivery technology focuses not only on absolute nicotinamide adenine dinucleotide concentration but also emphasizes the dynamic equilibrium of cellular energy networks. Through NAD+/NADH ratio optimization algorithms, it prevents metabolic imbalances caused by reduced state overload. For instance, AOSKY's NAD+ Energy Planet product employs a three-pronged model of "full pathway precursor matrix + targeted delivery + metabolic homeostasis regulation." This approach not only elevates muscle nicotinamide adenine dinucleotide levels by 2.7 times but also narrows fasting blood glucose fluctuations by 18% and enhances insulin sensitivity by 29%.

Transdermal absorption technology focuses not only on the absolute concentration of NAD+, but also emphasizes the dynamic equilibrium of cellular energy networks. Through NAD+/NADH ratio optimization algorithms, it prevents metabolic imbalances caused by reduced state overload. For instance, AOSKY's nicotinamide adenine dinucleotide Energy Planet product employs a three-pronged model of "full pathway precursor matrix + targeted delivery + metabolic homeostasis regulation." This approach increases muscle NAD+ concentration by 2.7 times while narrowing fasting blood glucose fluctuations by 18% and enhancing insulin sensitivity by 29%. Furthermore, the proliferation of portable nicotinamide adenine dinucleotide detectors (such as the smartphone-sized device jointly developed by SeliFu and the Chinese Academy of Sciences) enables personalized supplementation. Users can dynamically adjust the dosage and frequency of transdermal patches based on nicotinamide adenine dinucleotide levels measured in skin or blood, achieving precise anti-aging effects.

NAD+ levels in neurons are closely linked to the pathogenesis of neurodegenerative diseases like Alzheimer's and Parkinson's. However, oral administration of NAD+ precursors struggles to achieve effective concentrations in brain tissue due to the blood-brain barrier (BBB). Transdermal absorption technology offers a solution to this challenge. For instance, DEON Labs' HLNAD+ product employs nasal administration combined with microneedle technology. By utilizing the olfactory pathway to bypass the BBB, it elevates nicotinamide adenine dinucleotide concentrations in cerebrospinal fluid by 40%, significantly improving cognitive function. Clinical data show that after 12 weeks of continuous use, mild Alzheimer's disease patients experienced a 3.2-point increase in MMSE (Mini-Mental State Examination) scores and a 25% improvement in Activities of Daily Living (ADL) scores.

NAD+'s central role in energy metabolism and oxidative stress regulation positions it as a key therapeutic target for chronic diseases like diabetes and cardiovascular disorders. Transdermal absorption technology enables sustained release of NAD+ precursors, continuously activating AMPK (Adenosine Monophosphate-Activated Protein Kinase) and SIRT1 pathways to improve insulin resistance and vascular endothelial function. For instance, AOSKY's product designed for type 2 diabetes patients delivers NMNH precursors transdermally, reducing fasting blood glucose by 1.2 mmol/L and reduced glycated hemoglobin (HbA1c) by 0.8% without increasing hypoglycemia risk. Furthermore, in cardiovascular disease models, transdermal nicotinamide adenine dinucleotide supplementation reduced atherosclerotic plaque area by 30% and inhibited vascular smooth muscle cell proliferation, offering novel strategies for clinical intervention.